Ibandronat Pharmas

Active Ingredient:: Ibandronic Acid
Origin:: EU

Ibandronat Pharmas (Ibandronic Acid)

Q: What is Ibandronat Pharmas used for?

Ibandronat Pharmas contains ibandronic acid, a bisphosphonate indicated for the treatment of osteoporosis and for managing Paget's disease of bone. In osteoporosis, it helps lower the risk of vertebral and hip fractures, while in Paget's disease it normalizes bone turnover and reduces associated pain.

Q: How does Ibandronic Acid work?

Ibandronic Acid binds to hydroxyapatite at active bone remodeling sites. When osteoclasts attach, the drug is taken up and interferes with the mevalonate pathway, leading to osteoclast apoptosis. This suppresses bone resorption, allowing bone formation to predominate and improving overall bone density.

Q: What is the usual dose of Ibandronat Pharmas?

The specific dose and dosing schedule of Ibandronat Pharmas are determined by the prescribing clinician based on the patient’s condition, renal function, and other individual factors. Healthcare professionals should follow local prescribing guidelines and product labeling when initiating therapy.

Q: Is Ibandronat Pharmas safe during pregnancy or breastfeeding?

Safety data for ibandronic acid in pregnancy and lactation are limited. Because bisphosphonates may affect fetal bone development, the product is generally avoided in pregnant or nursing women unless the potential benefit justifies the potential risk. Consultation with a specialist is recommended.

Q: How do I order Ibandronat Pharmas from GNH India?

To request Ibandronat Pharmas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Ibandronat Pharmas compare with other bisphosphonates?

Ibandronat Pharmas is an oral bisphosphonate similar in class to alendronate and risedronate but differs in dosing frequency and potency. Ibandronate is often administered once monthly, offering a convenient schedule, while maintaining comparable efficacy in reducing fracture risk for osteoporosis.

Q: How should Ibandronat Pharmas be stored and handled?

Store Ibandronat Pharmas at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and excessive heat. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

Q: How is Ibandronat Pharmas administered?

Ibandronat Pharmas is taken orally with a full glass of water, preferably on an empty stomach. Patients should remain upright for at least 30 minutes after ingestion and avoid eating, drinking, or taking other medications during this period to enhance absorption and reduce esophageal irritation.

Q: What are the most serious risks associated with Ibandronat Pharmas?

The most serious adverse events linked to ibandronic acid include osteonecrosis of the jaw, atypical femur fractures, and severe esophagitis or esophageal ulceration. Prompt medical attention is required if patients experience persistent jaw pain, unusual thigh pain, or symptoms of severe gastrointestinal irritation.

Q: Who should not use Ibandronat Pharmas?

Ibandronat Pharmas should be avoided in patients with severe renal impairment (eGFR < 30 mL/min), active upper gastrointestinal disorders such as esophagitis or strictures, and those who are allergic to ibandronic acid or any excipients. Caution is also advised for individuals on multiple bisphosphonates or certain mineral supplements.

Ibandronic Acid, the active ingredient in Ibandronat Pharmas, is a bisphosphonate presented as an oral formulation for oral use. It is used to treat osteoporosis and Paget's disease of bone in adults at risk of fractures, helping to strengthen skeletal integrity and reduce bone turnover.

GNH India supplies Ibandronat Pharmas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products and reliable logistics across multiple regions. The company adheres to stringent regulatory standards and provides comprehensive support for import documentation and cold‑chain management where required.

Manufacturer / TM Owner

Pharmas D.O.O.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ibandronat Pharmas, a bisphosphonate, acts on bone remodeling pathways to improve skeletal health.

Osteoporosis: reduces risk of vertebral, hip and other fractures in postmenopausal women and men with osteoporosis.
Paget's disease of bone: normalizes abnormal bone turnover and alleviates bone pain associated with the disease.
Postmenopausal osteoporosis: increases bone mineral density and lowers incidence of fragility fractures in postmenopausal patients.

How It Works

Ibandronic Acid binds selectively to hydroxyapatite crystals at sites of active bone remodeling. When osteoclasts attach to the drug‑coated bone surface, the compound is internalized, disrupting the mevalonate pathway and inducing osteoclast apoptosis. This inhibition of osteoclast‑mediated bone resorption decreases bone turnover, leading to a net gain in bone mass and improved bone strength.

Side Effects

Ibandronat Pharmas may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
Constipation or diarrhea.
Headache.
Musculoskeletal pain.
Transient fever or flu‑like symptoms.

Serious or Rare Side Effects

Osteonecrosis of the jaw: severe bone loss in the jaw requiring dental evaluation.
Atypical femur fracture: low‑energy fracture of the subtrochanteric region.
Severe esophagitis or esophageal ulceration.
Hypersensitivity reactions: rash, angioedema or anaphylaxis.

Precautions & Warnings

Before initiating Ibandronat Pharmas, several safety considerations should be evaluated.

Renal function assessment: evaluate creatinine clearance and avoid use in severe renal impairment.
Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk.
Gastro‑esophageal disorders: screen for active esophagitis, strictures or dysphagia.
Concomitant NSAIDs or corticosteroids: use with caution due to increased gastrointestinal irritation.
Administration technique: advise patients to take with a full glass of water and remain upright for at least 30 minutes.
Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Avoid Interactions

Ibandronat Pharmas can interact with several medicines, affecting its absorption or safety profile.

Major Interactions (Avoid)

Concomitant oral bisphosphonates: may cause excessive suppression of bone turnover.
Antacids or mineral supplements containing calcium, magnesium, aluminum, or iron within 2 hours: markedly reduce ibandronate absorption.
NSAIDs, aspirin or corticosteroids: increase risk of upper gastrointestinal irritation or ulceration.
Severe renal impairment (eGFR <30 mL/min): contraindicated due to accumulation risk.

Moderate Interactions (Monitor Closely)

Warfarin: ibandronate may potentiate anticoagulant effect; monitor INR.
Diuretics (thiazides): may alter calcium balance; check serum calcium.
Hormone replacement therapy or selective estrogen receptor modulators: may modify bone turnover response.

Frequently Asked Questions

Ibandronat Pharmas contains ibandronic acid, a bisphosphonate indicated for the treatment of osteoporosis and for managing Paget's disease of bone. In osteoporosis, it helps lower the risk of vertebral and hip fractures, while in Paget's disease it normalizes bone turnover and reduces associated pain.

Ibandronic Acid binds to hydroxyapatite at active bone remodeling sites. When osteoclasts attach, the drug is taken up and interferes with the mevalonate pathway, leading to osteoclast apoptosis. This suppresses bone resorption, allowing bone formation to predominate and improving overall bone density.

The specific dose and dosing schedule of Ibandronat Pharmas are determined by the prescribing clinician based on the patient’s condition, renal function, and other individual factors. Healthcare professionals should follow local prescribing guidelines and product labeling when initiating therapy.

Safety data for ibandronic acid in pregnancy and lactation are limited. Because bisphosphonates may affect fetal bone development, the product is generally avoided in pregnant or nursing women unless the potential benefit justifies the potential risk. Consultation with a specialist is recommended.

To request Ibandronat Pharmas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ibandronat Pharmas is an oral bisphosphonate similar in class to alendronate and risedronate but differs in dosing frequency and potency. Ibandronate is often administered once monthly, offering a convenient schedule, while maintaining comparable efficacy in reducing fracture risk for osteoporosis.

Store Ibandronat Pharmas at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and excessive heat. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

Ibandronat Pharmas is taken orally with a full glass of water, preferably on an empty stomach. Patients should remain upright for at least 30 minutes after ingestion and avoid eating, drinking, or taking other medications during this period to enhance absorption and reduce esophageal irritation.

The most serious adverse events linked to ibandronic acid include osteonecrosis of the jaw, atypical femur fractures, and severe esophagitis or esophageal ulceration. Prompt medical attention is required if patients experience persistent jaw pain, unusual thigh pain, or symptoms of severe gastrointestinal irritation.

Ibandronat Pharmas should be avoided in patients with severe renal impairment (eGFR < 30 mL/min), active upper gastrointestinal disorders such as esophagitis or strictures, and those who are allergic to ibandronic acid or any excipients. Caution is also advised for individuals on multiple bisphosphonates or certain mineral supplements.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 31 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.